Get up to date on: A clinical understanding of glucagon-like-peptide-1 (GLP-1) agonists.

Diabetes is a worldwide epidemic. By 2050, it is projected that the number of people living with diabetes will more than double, reaching 1.3 billion globally.¹ Type 2 Diabetes Mellitus (T2DM) is a complex metabolic disorder that significantly reduces quality of life and leads to serious health complications.² Due to the increasing prevalence and associated complications of the disease, the need for effective treatment strategies is critical.